The prospective, open-label RESPOND study enrolled 1,014 patients at 41 centers in Europe, New Zealand, and Latin America, 31 (3.1%) of whom had bicuspid aortic valves. The mean age in the bicuspid patient cohort was 76.4 years, 64.5% were male, and the baseline STS score was 6.0 ± 10.2. Procedural success was 100%, with no cases of malpositioning, valve migration, embolization, or valve-in-valve. Repositioning was attempted in 10 cases (32.3%). There was one death (3.2%) and one stroke (3.2%) at 30-day follow-up. Mean AV gradient was reduced from 48.7 ± 17.0 mmHg at baseline to 11.8 ± 5.1 mmHg at hospital discharge (P < 0.001); mean effective orifice area (EOA) was increased from 0.6 ± 0.2 cm 2 to 1.7 ± 0.4 cm 2 (P < 0.001). There were no cases of moderate or severe paravalvular leak (PVL) adjudicated by the core laboratory; four subjects (13.8%) had mild PVL, 5 (17.2%) had trace PVL. The rate of pacemaker (PM) implantation for PM-naïve patients was 22.2% (6/27). 
| INTRODUCTION
Bicuspid valves are one of the most common congenital aortic valve anomalies, present in up to 2% of the population. 1, 2 Compared to tricuspid valves, bicuspid valves have a larger annulus perimeter, an asymmetrical valve orifice, and more heavily calcified leaflets/raphe. 3, 4 Patients with a bicuspid aortic valve are at increased risk for aortic stenosis, aortic dilation, aneurysm, and dissection. 3, 4 While transcatheter aortic valve implantation (TAVI) is an established treatment option for patients with symptomatic aortic stenosis who are at high risk for surgical valve replacement, 5, 6 patients with bicuspid valves have been excluded from most TAVI clinical trials and bicuspid-TAVI data are limited. Demonstrating safety and efficacy in bicuspid valves is essential for TAVI devices, particularly if TAVI is to be extended into lower risk populations in whom bicuspid anatomy is more prevalent.
Previous data have consistently shown worse outcomes following TAVI in bicuspid anatomy, including increased paravalvular leak (PVL), nonuniform/noncircular valve deployment, reduced procedural success, device migration/embolisation, malfunction, and annular rupture. [7] [8] [9] [10] [11] [12] [13] More recent studies have shown that outcomes may be better with newer generation valves. 8 The Boston Scientific Lotus
Valve has several features which may be of benefit in patients with bicuspid anatomy, including a sealing skirt to reduce PVL, deployment via gradual mechanical expansion, and full retrievability and repositionability. The REpostionable Percutaneous Replacement of stenotic aortic valve through Implantation of Lotus Valve System: Evaluation of safety and performance (REPRISE II) 14 2 | METHODS
| Study design and device details
The REpositionable Lotus Valve System-Post-market evaluation of real world clinical outcomes (RESPOND) study is a prospective, open label, single arm, multi-center, post-market registry from 41 centers in Europe, New Zealand, and Latin America. The study design has been previously described. 16 Data collection occurred at baseline, index procedure, discharge and at 30 days and 1 year postprocedure for all enrolled subjects. 
| Outcomes measures
Endpoints were assessed according to Valve Academic Research Consortium (VARC)-2 definitions. 19 The primary endpoint for RESPOND was all-cause mortality at 30 days and 1 year in the intent-to-treat population. Secondary endpoints included in-hospital mortality, the composite of all-cause mortality and disabling stroke at 30 days and 1 year, and grade of paravalvular aortic valve regurgitation at discharge and 1 year.
Major clinical events (i.e., all-cause mortality and stroke events) were adjudicated by an Independent Medical Reviewer (IMR). All baseline and follow-up echocardiography data were evaluated by an independent core laboratory (Cardialysis Core Laboratory, Rotterdam, Netherlands).
For this subanalysis, the preliminary identification of bicuspid anatomy was site-reported, and verified on the basis of echocardiography and/or computerized tomography (CT) coronary angiography. 3 | RESULTS
| Study participants and baseline characteristics
The RESPOND post-market registry enrolled 1,014 patients between were similar. Significant baseline differences existed for average age (76.4 ± 7.9 years bicuspid vs. 80.9 ± 6.4 years tricuspid; P < 0.001), history of coronary artery disease (CAD) (25.8% bicuspid vs. 57.1% tricuspid; P = 0.001), and percutaneous coronary intervention (PCI) (12.9% bicuspid vs. 30.4% tricuspid; P < 0.05) ( Table 1 ). for tricuspid (P = 0.008) and the mean aortic valve gradient was 48.7 ± 17.0 mmHg for bicuspid and 37.6 ± 15.3 mmHg for tricuspid (P < 0.001). There were no significant differences in aortic regurgitation (AR) at baseline (Severe AR: 3.7% for bicuspid, 2.2% for tricuspid;
Moderate AR: 18.5% for bicuspid, 14.2% for tricuspid; None-Mild AR:
77.8% for bicuspid, 83.6% for tricuspid; P=NS for all). Site-reported aortic valve calcification was not significantly different in patients with bicuspid valves versus patients with tricuspid aortic valves (Table 1) , nor was site-reported aortic annulus diameter (25.1 mm for bicuspid, 24.4 mm for tricuspid; P = 0.085). Based on preprocedural echocardiography, left ventricular ejection fraction was similar in both groups (50.9 ± 15.3% for bicuspid, 54.8 ± 13.0% for tricuspid; P = 0.112).
There were 11 (35.4%) aortic root aneurysms (defined as maximum diameter of ascending aorta >40 mm) reported in the bicuspid cohort of the RESPOND registry. patients. In the one bicuspid patient in whom repositioning was deemed unsuccessful, the site had reported "moderate aortic regurgitation (Figure 2A ).
| Procedural success and details

| Haemodynamic performance
The 
| Safety
The primary endpoint of all-cause mortality was not significantly different between the bicuspid and tricuspid cohorts at 30 days (3.2% vs. 2.2%, respectively; P = 0.51) or 1 year (9.7% vs. 11.7%, respectively; Mean aortic valve gradient and effective orifice area. Bicuspid and tricuspid patients both demonstrated a significant change in mean aortic valve gradient and effective orifice area (EOA) from baseline to discharge, which was maintained at 1 year. Baseline measurements for mean aortic gradient and mean EOA were different between the bicuspid and tricuspid cohorts at baseline, with no significant difference observed between groups at discharge or 1 year post-TAVI. Data is core laboratory adjudicated [Color figure can be viewed at wileyonlinelibrary.com] P = 0.74). There were no significant differences between groups for other principal safety outcomes through 1 year, including cardiovascular mortality, stroke, hospitalization for valve-related symptoms or worsening congestive heart failure, and pacemaker implantation ( Figure 5 ).
| Valve sizing in bicuspid anatomy
Annulus diameter measurements were performed by each site and valve sizing was determined at the discretion of the operator. tricuspid; P = 0.04) ( Figure 2B , Table 2 ). Of the 31 patients with bicuspid anatomy, five had considerable (>10%) undersizing by annulus area. Echocardiographic data indicates that PVL and haemodynamic results were good in these patients (Table 3) .
| DISCUSSION
The principal finding of this study is that outcomes for patients with bicuspid aortic valves who underwent TAVI with the Lotus Valve in the "real-world" RESPOND registry were comparable to those with 
| Challenges of TAVI in bicuspid anatomy
Due to the high level of calcification and eccentric geometry in patients with bicuspid anatomy, TAVI in bicuspid valves may be subject to an increased risk of complications related to irregular and incomplete expansion of the prosthetic valve. 9 Asymmetrical expansion of valves has been observed as high as 38% with the S3 valve in bicuspid anatomy 10 Information Table S1 ). This similarity may be attributed to the independent mobility of the Lotus valve leaflets. The Lotus Valve is designed such that the leaflets are not sutured to the valve frame, and are therefore not affected by non-circular valve expansion.
Furthermore, heavy calcification and eccentricity of the native annulus increases the risk of device malapposition and consequently of PVL. In a comparative analysis from the German TAVI Registry of bicuspid vs. tricuspid valves, the risk for moderate or greater AR was higher in patients with bicuspid anatomy receiving CoreValve or Sapien. 12 Mylotte et al. similarly reported a high incidence of postimplant AR in 139 bicuspid patients undergoing TAVI with Sapien XT and CoreValve (AR grade ≥ 2 was 28.4%). 13 In tricuspid anatomy, the Device success is typically lower overall for bicuspid TAVI-patients as compared to tricuspid TAVI-patients. 8 The use of balloon-expanded valves has been associated with an increased risk of annular rupture due to overdilation of the prosthesis to treat residual paravalvular regurgitation. 21 The Lotus Valve is fully repositionable and retrievable, 
| Valve sizing in bicuspid anatomy
For the RESPOND registry, sizing of the valve was at the discretion of the implanter. Some clinicians have hypothesized that routine undersizing may be beneficial in bicuspid anatomy, allowing fixation and sealing within the leaflets, with more complete and symmetrical expansion of the valve frame to optimize haemodynamics and potentially enhance long-term durability. In this analysis five patients received valves that had >10% undersizing by area; all had good outcomes with respect to PVL and valve haemodynamics.
Other studies have shown a tendency to oversize TAVI devices in bicuspid anatomy in an effort to circularize the annulus, prevent malpositioning, and reduce PVL, even though oversizing may increase the [23] [24] [25] However, it is difficult to draw a definitive conclusion regarding the incidence of PVL as a function of valve oversizing among bicuspid patients in RESPOND, chiefly due to the small sample size and low rate of PVL overall in this study. Further examination is needed to determine whether specific baseline and/or procedural characteristics influence the development of PVL in bicuspid patients treated with the Lotus Valve.
| Study limitations
The primary limitation of this study is the small size of the analysis population. Additionally, RESPOND is a single-arm registry, and not a randomized study. Preliminary identification of bicuspid anatomy was site-reported, and although central CT analysis was used to confirm bicuspid anatomy, it was unfortunately not possible to review baseline CT scans for all RESPOND patients. In RESPOND, 3% of patients were identified as having bicuspid aortic valve stenosis; however, other studies have shown an incidence of approximately 20%. 2 It is possible that initial identification via echocardiography failed to capture all patients with bicuspid anatomy, underestimating the true number of bicuspid patients in the population. An additional limitation is that at the time of this study, the largest available Lotus Valve was 27 mm, which limits the results to patients with smaller annular diameters.
| CONCLUSIONS
TAVI with the Lotus Valve in patients with bicuspid aortic valve anatomy treated within the RESPOND registry was associated with good procedural, clinical, and haemodynamic outcomes.
